The Biden administration on Oct. 21 issued a new proposed rule that would require health insurance providers to cover an injectable form of the HIV prevention medication known as PrEP, marking a ...

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...